✦ LIBER ✦
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
✍ Scribed by K. Fizazi; J.S. De Bono; A. Flechon; A. Heidenreich; E. Voog; N.B. Davis; Ming Qi; R. Bandekar; J.T. Vermeulen; M. Cornfeld; G.R. Hudes
- Book ID
- 116430907
- Publisher
- Elsevier Science
- Year
- 2012
- Tongue
- English
- Weight
- 336 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0959-8049
No coin nor oath required. For personal study only.